Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. 

Humans produce over 4,000 distinct extracellular proteins, more than 1,000 of which can drive disease when they act improperly, misfold, or are made at the wrong time, in the wrong place, or at incorrect levels. By eliminating these disease-causing proteins, we aim to eliminate diseases for patients.

Molecular Gates act by a completely new therapeutic mechanism. All extracellular proteins pass through single channel in the cell as they are secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the harmful protein is degraded by the cell instead of being secreted.

Our mission to create Molecular Gate medicines is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at www.gatebio.com.


Biotechnology

Gate Bioscience

Jordi Mata-Fink

Clare Ozawa

Brian Cathers

The Research and Development team at Gate Bioscience is dedicated to advancing the pioneering technology of Molecular Gates. This multidisciplinary team conducts innovative research to design and optimize small molecule compounds, assesses their efficacy in targeting harmful extracellular proteins, and utilizes data science to analyze results and inform future strategies. Their collaborative efforts aim to translate groundbreaking concepts into viable preclinical therapies that offer new treatment options for disease mitigation.

Research and Development

About

Team members

Other teams at Gate Bioscience

Leadership Team